News

LB Select
2025.08.08 08:18

Zhonghui Biotech surged 168% in the dark market, and the public offering reportedly recorded over 4,000 times oversubscription, amounting to over HKD 200 billion, becoming the most oversubscribed IPO in the Hong Kong stock market this year for biotech companies. The winning rate is extremely low.

Zhonghui Biotech is a vaccine company dedicated to the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods. Currently, Zhonghui Biotech has two core products, namely the quadrivalent influenza virus subunit vaccine (brand name "Hui Er Kang Xin") and the under-research lyophilized human rabies vaccine (developed using human diploid cells, which has good safety); as well as 11 other under-research vaccines covering multiple disease areas with a huge demand for vaccination

Source: LB Select The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.